Lead Product(s): Enmetazobactam,Cefepime
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2020
EXBLIFEP demonstrated superiority in the primary endpoint of clinical cure and microbiological eradication at test-of-cure over piperacillin-tazobactam.